Payload Information
General Information of This Payload
| Payload ID | PAY0EIIJT |
|||||
|---|---|---|---|---|---|---|
| Name | Pseudomonas exotoxin LO10R456A |
|||||
| Synonyms |
Pseudomonas exotoxin LO10R456A
Click to Show/Hide
|
|||||
| Target(s) | Eukaryotic elongation factor 2 (EEF2) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
LMB-100 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.43% (Day 6) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.60% (Day 15) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.30% (Day 9) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.70% (Day 9) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Oxaliplatin.
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.28% (Day 15) | Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Actinomycin D (0.3 mg/kg).
|
||||
| In Vivo Model | SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.55 ng/mL±0.06 ng/mL
|
Positive MSLN expression (MSLN +++/++) | ||
| Method Description |
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.